-
BMC Ophthalmology Nov 2017Anti-fibrotic, anti-VEGF (vascular endothelial growth factor) medications, or radiotherapy, as adjuvant for pterygium surgical procedure, has been suggested for reducing... (Meta-Analysis)
Meta-Analysis Review
BACKGROUND
Anti-fibrotic, anti-VEGF (vascular endothelial growth factor) medications, or radiotherapy, as adjuvant for pterygium surgical procedure, has been suggested for reducing recurrence, but difficulties may be experienced in deciding which treatment to use. The purpose of this study was to compare the efficacies of these different adjuvants for preventing recurrence following pterygium surgery.
METHODS
We conducted a systematic review to identify randomized controlled trials of patients with primary or recurrent pterygium who received anti-fibrotic, anti-VEGF medication, or radiotherapy as adjuvants in combination with surgical procedure. The surgical procedure contained bare sclera technique or petrygium excision combination with tissue grafting. The primary outcome of this study was recurrence. Direct-comparison and Bayesian network meta-analyses were performed to assess direct and indirect evidence of efficacy.
RESULTS
We obtained data from 34 randomized controlled trials, representing a total of 2483 patients. Adjuvants included bevacizumab, 5-FU (5-fluorouracil), MMC (mitomycin C), and β-RT (beta-radiotherapy). Compared with placebo, we found distinguishable improvement in recurrence with bevacizumab (odds ratio [OR] 0.38, 95% confidence interval [CI] 0.18-0.80), MMC (0.12, 95% CI 0.06-0.21), and β-RT (0.17, 95% CI 0.04-0.69), but not with 5-FU (0.41, 95% CI 0.12-1.39). MMC significantly reduced recurrence when compared to bevacizumab (0.31, 95% CI 0.13-0.77) and 5-FU (0.28, 95% CI 0.08-0.99). The probability of having the most recurrences after excision was lowest for MMC, followed by bevacizumab and β-RT. Similar results were found in subgroup analyses, including for primary pterygium, and the patients receiving bare sclera technique or conjunctival autograft.
CONCLUSIONS
Adjuvants such as MMC, bevacizumab, and β-RT could effectively prevent recurrence following pterygium excision. However, their efficacy and acceptability require further clarification in future randomized controlled trials.
Topics: Alkylating Agents; Angiogenesis Inhibitors; Antifibrinolytic Agents; Chemotherapy, Adjuvant; Humans; Ophthalmologic Surgical Procedures; Primary Prevention; Pterygium; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Recurrence; Secondary Prevention; Vascular Endothelial Growth Factor A
PubMed: 29178848
DOI: 10.1186/s12886-017-0601-5 -
Investigative Ophthalmology & Visual... Sep 2014To determine the association of cigarette smoking with pterygium. (Meta-Analysis)
Meta-Analysis Review
PURPOSE
To determine the association of cigarette smoking with pterygium.
METHODS
Potentially eligible studies published from the year 1946 to December 28, 2013 were identified from MEDLINE, EMBASE, and Cochrane Library databases, and reference lists. All studies that evaluated smoking as an independent factor for pterygium were identified. Study-specific odds ratios (ORs) were combined using the random-effects model when P < 0.1 in the test for heterogeneity, or otherwise the fixed-effects model was used. Meta-regression, sensitivity analysis, and evaluation of potential biases were undertaken. The ORs with 95% confidence intervals (CIs) of smoking as an associated factor for pterygium were analyzed.
RESULTS
We included 24 articles incorporating 95,279 participants from 20 cross-sectional studies, 2 hospital-based case-control studies, and 2 population-based cohort studies. The combined OR of cigarette smoking (current or ever smoked) for risk of pterygium was 0.82 (95% CI, 0.69-0.97; P = 0.025). The results remained consistent among current smokers (OR, 0.68; 95% CI, 0.61-0.76; P = 4.57 × 10(-12)), but not in ex-smokers (OR, 1.05; 95% CI, 0.87-1.27; P = 0.59). The impact of ultraviolet light (UV) exposure (P = 0.082) and sex (P = 0.553) on the effect of smoking was insignificant in meta-regression. Sensitivity analysis confirmed the protective effect and nonrelevance of these two study-level variables. Begg's funnel plots and Egger's test showed minimal publication bias.
CONCLUSIONS
The results of this meta-analysis show that cigarette smoking was associated with a reduced risk of pterygium, especially in current smokers. This effect may be independent of UV exposure and sex. Investigations are needed to unveil its molecular basis serving therapeutic purposes.
Topics: Global Health; Humans; Morbidity; Prognosis; Pterygium; Risk Assessment; Risk Factors; Smoking
PubMed: 25190665
DOI: 10.1167/iovs.14-15046 -
BMJ Open Nov 2013Pterygium is considered to be a proliferative overgrowth of bulbar conjunctiva that can induce significant astigmatism and cause visual impairment; this is the first...
OBJECTIVE
Pterygium is considered to be a proliferative overgrowth of bulbar conjunctiva that can induce significant astigmatism and cause visual impairment; this is the first meta-analysis to investigate the pooled prevalence and risk factors for pterygium in the global world.
DESIGN
A systematic review and meta-analysis of population-based studies.
SETTING
International.
PARTICIPANTS
A total of 20 studies with 900 545 samples were included.
PRIMARY OUTCOME MEASURE
The pooled prevalence and risk factors for pterygium.
RESULTS
20 studies were included. The pooled prevalence of pterygium was 10.2% (95% CI 6.3% to 16.1%). The pooled prevalence among men was higher than that among women (14.5% vs 13.6%). The proportion of participants with unilateral cases of pterygium was higher than that of participants with bilateral cases of pterygium. We found a trend that the higher pooled prevalence of pterygium was associated with decreasing geographical latitude and age in the world. The pooled OR was 2.32 (95% CI 1.66 to 3.23) for the male gender and 1.76 (95% CI 1.55 to 2.00) for outdoor activity, respectively.
CONCLUSIONS
The pooled prevalence of pterygium was relatively high, especially for low latitude regions and the elderly. There were many modifiable risk factors associated with pterygium to which healthcare providers should pay more attention.
PubMed: 24253031
DOI: 10.1136/bmjopen-2013-003787 -
Saudi Journal of Ophthalmology :... 2023To compare the outcomes of fibrin glue versus sutures in pterygium surgery with amniotic membrane transplantation.
PURPOSE
To compare the outcomes of fibrin glue versus sutures in pterygium surgery with amniotic membrane transplantation.
METHODS
A systematic review and meta-analysis were performed as per the Preferred Reporting Items for Systematic Reviews and Meta-analyses Guidelines. An electronic search identified all studies comparing the outcomes of using fibrin glue versus sutures in pterygium surgery with amniotic membrane transplantation. Conjunctival inflammation, postoperative pain and discomfort, pterygium recurrence, pyogenic granuloma, and surgical time were primary outcome measures. Secondary outcome measures included amniotic membrane transplant outcomes, time to recurrence, graft loss, and subconjunctival hemorrhage. Fixed and random-effects models were used for the analysis.
RESULTS
Four studies enrolling 180 patients were identified. Conjunctival inflammation (odds ratio [OR] 0.21, = 0.0005) demonstrated a significant difference favoring the fibrin glue group. Despite the trend favoring the use of fibrin glue, there were no significant differences in terms of postoperative pain and discomfort (OR = 0.46, = 0.25), pterygium recurrence (OR = 0.74, = 0.48), pyogenic granuloma (OR = 0.47, = 0.38), and surgical time (mean difference = -17.52, = 0.13). For secondary outcomes, fibrin glue had significantly fewer cases of graft loss compared with sutures. No statistically significant difference was found in amniotic membrane graft outcomes, time to recurrence, and subconjunctival hemorrhage.
CONCLUSION
Fibrin glue is comparable to the sutures used in pterygium surgery with amniotic membrane transplantation as it significantly improves conjunctival inflammation and does not increase postoperative pain and discomfort, pterygium recurrence, pyogenic granuloma, and surgical time.
PubMed: 37492203
DOI: 10.4103/sjopt.sjopt_143_22 -
Frontiers in Medicine 2022Pterygium is a common ocular surface disease. Recurrence is the greatest concern in the treatment of pterygium. Thus, a standardized and effective treatment modality...
BACKGROUND
Pterygium is a common ocular surface disease. Recurrence is the greatest concern in the treatment of pterygium. Thus, a standardized and effective treatment modality with minimal risk for complications is needed for the management of pterygium. The aim of this systematic review and meta-analysis was to evaluate different tissue grafting options, including conjunctival autograft (CAG) with mitomycin C (MMC), CAG alone, and amniotic membrane transplantation (AMT), for the management of primary pterygium.
METHODS
We searched the MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials databases for relevant studies. We included randomized controlled trials (RCTs) in which CAG + MMC and AMT were compared with surgical excision with CAG alone for the treatment of primary pterygium. The rates of recurrence and adverse events reported in the studies were also evaluated. Risk ratio (RR) was used to represent dichotomous outcomes. The data were pooled using the inverse variance weighting method. The quality of the evidence derived from the analysis was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Risk of bias was assessed using the revised Cochrane risk-of-bias tool for randomized trials.
RESULTS
Twelve RCTs ( = 1144) were deemed eligible and included for analysis. Five RCTs had a low risk of bias, five had some concerns, and two had a high risk of bias. Subgroup analysis showed a statistically significant reduction in the rate of pterygium recurrence after CAG + MMC (RR = 0.12; 95% confidence interval [CI], 0.02-0.63). This outcome was rated as high-quality evidence according to the GRADE criteria. There were insignificant differences between the rates of recurrence after AMT and CAG (RR = 1.51; 95% CI, 0.63-3.65). However, this result was rated as low-quality evidence. Regarding adverse events, patients treated using AMT showed significantly lower rates of adverse events than those treated using CAG (RR = 0.46; 95% CI, 0.22-0.95). However, this finding was rated as low-quality evidence as well. CAG + MMC showed a safety profile comparable to that of surgical excision with CAG alone (RR = 1.81; 95% CI, 0.40-8.31). This result was also rated as low-quality evidence.
CONCLUSION
A single intraoperative topical application of 0.02% MMC during excision of pterygium followed by CAG has significantly shown to decrease the rate of pterygium recurrence to 1.4% with no severe complications.
PubMed: 36438046
DOI: 10.3389/fmed.2022.981663 -
Oncotarget Jun 2017Previous meta-analyses have been conducted to compare the efficacy of fibrin glue (FG) versus sutures in pterygium surgery; however, additional clinical trials have... (Meta-Analysis)
Meta-Analysis Review
Efficacy of fibrin glue versus sutures for attaching conjunctival autografts in pterygium surgery: a systematic review with meta-analysis and trial sequential analysis of evidence.
Previous meta-analyses have been conducted to compare the efficacy of fibrin glue (FG) versus sutures in pterygium surgery; however, additional clinical trials have since been published. Therefore, we conducted an updated meta-analysis to further explore the association between FG application in pterygium surgery, and the recurrence rate, complication rate, and surgical duration. An electronic literature search for eligible studies published before July 29, 2016 was conducted across multiple databases. Odds ratios (ORs), standardized mean difference (SMD), and 95% confidence intervals (CI) were calculated. Publication bias of the included articles was evaluated by funnel plots. Differences in recurrence rate and complication rate between the FG and suture groups were evaluated in terms of OR with 95% CI, and SMD with 95% CI were used to estimate the difference in surgical duration. Trial sequential analysis (TSA) was used to determine whether the currently available evidence was sufficient and conclusive. Twenty-four studies were included in this study. The pooled ORs for recurrence rate and complication rate were 0.35 and 1.121, respectively. The pooled SMD for surgical duration was -4.142. The TSA results indicated that evidence of the effect was sufficient in the recurrence group and surgical duration group. Although there was no difference in complication rate between FG and sutures, the apparent advantages of FG over sutures are shorter surgical duration and greater reduction in the recurrence rate of pterygium.
Topics: Adult; Autografts; Conjunctiva; Fibrin Tissue Adhesive; Humans; Middle Aged; Pterygium; Randomized Controlled Trials as Topic
PubMed: 28489563
DOI: 10.18632/oncotarget.17195 -
Graefe's Archive For Clinical and... May 2024To evaluate the effects of different pterygium surgery techniques on ocular surface (OS) in different follow-up periods. (Meta-Analysis)
Meta-Analysis Review
PURPOSE
To evaluate the effects of different pterygium surgery techniques on ocular surface (OS) in different follow-up periods.
METHODS
PubMed, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wan Fang, and China Biology Medicine disc were searched for studies reporting pre- and post-operative OS parameters in pterygium.
RESULTS
A total of 33 articles were finally included. Three OS parameters showed relatively consistent changing trends after surgery including ocular surface disease index (OSDI), tear film break-up time (BUT), and score of corneal fluorescein staining (SCFS). They worsened significantly at 1w post-operation and then gradually improved: OSDI and BUT showed obvious improvement in 1 m post-operation (SMD = - 0.58, 95%CI = [- 1.04, - 0.13]; SMD = 0.42, 95%CI = [0.06, 0.78]); SCFS was restored to preoperative levels in 3 m after surgery (SMD = - 0.54, 95%CI = [- 1.16, 0.07]). Another parameter, Schirmer test without anesthesia (SIT), presented transient increase at 1w post-operation (SMD = 0.87, 95%CI = [0.27, 1.47]) and presented a relatively stable improvement after 1 m post-operation (SMD = 0.52, 95%CI = [0.16, 0.89]). All parameters in amniotic membrane graft (AMT) showed better improvement in early stage and they showed non-inferior improvements in the long term compared with conjunctival autograft (CAG). Limbal-conjunctival autograft (LCAG) made excellent improvement to OS in the long term while pterygium excision (PE) showed the worst OS. The type of pterygium (primary and secondary), diabetes mellitus (DM) status, and fixation method had certain effects on the results.
CONCLUSIONS
OS of pterygium is deteriorated at 1w post-operation then gradually improved to preoperative levels after 1 m post-operation. Among various surgery techniques, LCAG had the best improvement to OS which especially displayed in the long-term outcomes.
Topics: Humans; Pterygium; Neoplasm Recurrence, Local; Conjunctiva; Transplantation, Autologous; Recurrence; Follow-Up Studies
PubMed: 37581652
DOI: 10.1007/s00417-023-06191-1 -
International Journal of Ophthalmology 2017To evaluate the clinical effect of bevacizumab in pterygium treatment.
AIM
To evaluate the clinical effect of bevacizumab in pterygium treatment.
METHODS
A systematic review and quantitative Meta-analysis was performed. PubMed, EMBASE, Web of Science and Cochrane database were searched for eligible literatures published in English until June 2016. The endpoint was recurrence rate and pooled risk ratio (RR) was calculated.
RESULTS
Nine eligible studies were included and Meta-analysis results showed no significantly difference in patients treated with bevacizumab in short term follow-up [3mo: RR=0.70 (0.34, 1.45); 6mo: RR=0.55 (0.23, 1.32)] compared with control groups. No significant effects were observed in favor of bevacizumab in subgroup analyses: patients with subconjunctival injection of bevacizumab [3mo: RR=0.95 (0.70, 1.29); 6mo: RR=0.83 (0.55, 1.28)], primary pterygium [3mo: RR=0.59 (0.23, 1.54; 6mo: RR=0.59 (0.23, 1.53)], simple pterygium excision [3mo: 0.32 (0.05, 2.04), =0.23; 6mo: 0.27 (0.05, 1.53)] and excision with conjunctival autograft [3mo: 1.51 (0.25, 9.15); 6mo: 1.11 (0.06, 21.69)].
CONCLUSION
In this Meta-analysis, we did not found the significant effect of bevacizumab in pterygium treatment, at least in short term follow-up (3mo and 6mo).
PubMed: 28730117
DOI: 10.18240/ijo.2017.07.17 -
Medicine Aug 2018Anti-VEGF agents has been widely used in ocular diseases, but its safety for treating anterior segment disorders, the conclusions are controversial. (Meta-Analysis)
Meta-Analysis Review
Safety of antivascular endothelial growth factor administration in the ocular anterior segment in pterygium and neovascular glaucoma treatment: Systematic review and meta-analysis.
BACKGROUND
Anti-VEGF agents has been widely used in ocular diseases, but its safety for treating anterior segment disorders, the conclusions are controversial.
METHODS
Several major databases, including CENTRAL, MEDLINE, and EMBASE, were searched. Safety data from 18 randomized controlled trials (RCTs) were used to compare anti-VEGF treatment in the ocular anterior segment in pterygium and neovascular glaucoma treatment with placebo/sham treatment for eye diseases. A meta-analysis for adverse events was performed.
RESULTS
Eighteen RCT studies with 955 eyes were included in the meta-analysis. Significant difference in conjunctival disorders (OR: 1.62; 95% CI, 1.01-2.59; P = .05) was noted among the included studies, but not in ocular intolerance (odds ratio [OR]: 0.75; 95% CI, 0.34-1.62; P = .46), corneal disorders (OR: 0.71; 95% CI, 0.37-1.37; P = .31), or the subgroup analysis of conjunctival disorders.
CONCLUSIONS
The administration of anti-VEGF agents in the ocular anterior segment for patients with pterygium and glaucoma was tolerable in tolerance and cornea, but was the risk factor of conjunctival disorders. The healing of corneal epithelium may be delayed in patients with primary corneal epithelial defects after anti-VEGF application. However, due to the limited evidence, further research should be performed on the safety of anti-VEGF administration in patients with different corneal disorders.
Topics: Administration, Ophthalmic; Aged; Angiogenesis Inhibitors; Bevacizumab; Female; Glaucoma, Neovascular; Humans; Male; Middle Aged; Pterygium; Treatment Outcome
PubMed: 30142821
DOI: 10.1097/MD.0000000000011960 -
International Journal of Environmental... Dec 2017Pterygium is a chronic eye disease: among its recognized risk factors there is long-term exposure to ultraviolet (UV) radiation. The Sun is the main source of UV... (Review)
Review
Pterygium is a chronic eye disease: among its recognized risk factors there is long-term exposure to ultraviolet (UV) radiation. The Sun is the main source of UV exposure: according to the World Health Organization, the Population Attributable Fraction of pterygium due to solar radiation (SR) is 42-74%. Outdoor work can deeply influence the eye exposure to solar UV rays, but, despite this, pterygium is currently not adequately considered as a possible occupational disease in this working category, at least in Europe. For this reason, we performed a systematic review of the scientific literature published in the last ten years (2008-2017) considering the role of outdoor work as a risk factor for pterygium, in order to give new support for the prevention of this UV related disease in workers. We identified 29 relevant papers. Our results show that pterygium prevalence highly increased with latitude and mean annual UV index, and outdoor work is one of the most relevant risk factors, as well as age and male sex, both in high risk and in moderate risk World areas considering the environmental UV levels. Accordingly, pterygium occurring in outdoor workers should be considered an occupational disease. Moreover, our findings clearly support the need of further research on more effective prevention of the occupational risk related to long-term solar radiation exposure of the eye.
Topics: Europe; Female; Humans; Male; Occupational Exposure; Pterygium; Risk Assessment; Risk Factors; Sunlight; Ultraviolet Rays
PubMed: 29278403
DOI: 10.3390/ijerph15010037